Cytokine signatures in chronic fatigue syndrome patients: a Case Control Study and the effect of anakinra treatment.
Roerink, Megan E, Knoop, Hans, Bronkhorst, Ewald M et al. · Journal of translational medicine · 2017 · DOI
Quick Summary
Researchers compared immune signaling molecules (cytokines) in the blood of 50 women with ME/CFS to 48 healthy women and found two markers were elevated in the ME/CFS group: IL-12p40 and CSF-1. They also tested whether a drug called anakinra (which blocks inflammation) could help reduce these markers, but found it did not significantly change cytokine levels after 4 weeks of treatment.
Why It Matters
This study identifies specific immune signaling molecules that may help distinguish ME/CFS patients from healthy individuals, potentially supporting better diagnostic approaches. The finding that anakinra did not improve the cytokine profile, despite targeting a plausible inflammatory pathway, refines understanding of which immune interventions may or may not be effective in ME/CFS.
Observed Findings
IL-12p40 expression was significantly elevated in CFS/ME patients compared to controls (p=0.0042)
CSF-1 expression was significantly elevated in CFS/ME patients compared to controls (p=0.049)
A predictive model combining 47 inflammatory markers achieved corrected AUC=0.73 for distinguishing patients from controls
Anakinra treatment had no significant effect on circulating cytokine levels after 4 weeks and multiple-testing correction
TGF-β levels did not differ between CFS/ME patients and healthy controls
Inferred Conclusions
Immune pathway dysregulation in ME/CFS includes alterations in IL-12p40 and CSF-1, which may reflect aberrant Th1/Th17 cell differentiation and myeloid lineage dysfunction
Multimarker immune signatures may have diagnostic or prognostic utility in ME/CFS
Blocking the IL-1 pathway alone is insufficient to normalize the circulating cytokine profile in ME/CFS, suggesting either redundant inflammatory pathways or that cytokine abnormalities are secondary rather than primary drivers
Remaining Questions
Do IL-12p40 and CSF-1 elevation correlate with symptom severity, disease duration, or post-exertional malaise, and do they change with symptom fluctuation?
Would targeting alternative cytokine pathways (such as TNF-α, IL-6, or IFN-γ) or combination anti-inflammatory approaches be more effective than IL-1 antagonism alone?
What This Study Does Not Prove
This study does not prove that IL-12p40 and CSF-1 elevation *causes* ME/CFS symptoms—they may be markers of the condition rather than drivers of it. It also does not rule out that longer treatment duration or higher doses of anakinra might have different effects, nor does it determine whether these cytokines correlate with symptom severity or clinical response. The small sample size and female-only cohort limit generalizability.
Are the observed cytokine abnormalities present across both sexes and different ME/CFS patient subgroups, or are they specific to this cohort?
What is the functional significance of the 47-marker predictive panel, and which individual markers drive the discrimination between patients and controls?